viewAcasti Pharma Inc

Acasti Pharma to investors: We're not planning a capital raise

The company refuted the notion that corporate developments were behind an uptick in the share price and trading volume

Since July 17, its share price has jumped from $1.37 to as high as $2.34

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) stock is on the rise, but it isn’t because a capital raise is in the works.

The biopharmaceutical company refuted the notion Thursday that any corporate developments were behind a recent uptick in both share price and trading volume.

Since July 17, its share price has jumped from US$1.37 to as high as $2.44, and its average trading volume is up to nearly 6 million compared to its three month average of 1.1 million.

One reason for the recent surge could be a series of analyst notes published in July. On July 18, Oppenheimer initiated coverage of the stock with a $7 price target, per StreetInsider, and analyst Gene Katx upped his price target to $11.06 on July 23.

READ: Two prominent research firms initiate coverage on Acasti Pharma with Buy rating

One possible draw for investors is its omega-3 drug candidate CaPre, which is currently undergoing Phase 3 clinical trials. The Laval, Quebec-based company expects to reports from its TRILOGY 1 trial in December 2019 and its TRILOGY 2 trial in January 2020.

In a statement, Acasti reiterated that the company has enough funding to complete the trials of the drug. Of March 31, the company had $34.4 million in cash, cash equivalents and marketable securities on hand.

CaPre is designed to treat hypertriglyceridemia, a condition characterized by elevated triglyceride levels in the blood. Acasti plans to submit a New Drug Application to the US Food and Drug Administration in mid-2020.

Investors gave back some of Acasti's gains on Thursday, dropping the share price 9.8% to C$2.76 in Toronto and 10% to $2.10 on OTC Markets.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Acasti Pharma Inc

Price: 0.87 CAD

Market: TSX-V
Market Cap: $78.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...



Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 26/11/19

2 min read